Although back pain is uncommon, certain individuals are at greater risk
Retatrutide may become an option in the future if: Its approved by the MHRA and recommended by NICE, which is likely several years away You havent responded well to existing GLP-1 medications, and a triple agonist offers a different approach worth trying The Phase 3 safety data on heart rate, irregular heartbeats, and dysesthesia are reassuring once its complete For most people in the UK, the choice now is between Wegovy and Mounjaro, supported by a structured weight management service
Some clinicians combine agents with complementary mechanisms
Many users also notice improvements in digestion, stabilized blood sugar, reduced inflammation, and better emotional resilience and cognitive clarity
Rare but serious adverse effects including pancreatitis, gallbladder disease, or severe allergic reactions may require immediate cessation
Our IV therapy pricing is transparent and listed on each product listing